PACIRA BIOSCIENCES INC (PCRX) Stock Fundamental Analysis

NASDAQ:PCRX • US6951271005

21.91 USD
-0.68 (-3.01%)
At close: Feb 27, 2026
21.91 USD
0 (0%)
After Hours: 2/27/2026, 8:26:16 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

6

Overall PCRX gets a fundamental rating of 6 out of 10. We evaluated PCRX against 192 industry peers in the Pharmaceuticals industry. PCRX scores excellent on profitability, but there are some minor concerns on its financial health. PCRX is cheap, but on the other hand it scores bad on growth. These ratings could make PCRX a good candidate for value investing.


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

  • In the past year PCRX was profitable.
  • PCRX had a positive operating cash flow in the past year.
  • The reported net income has been mixed in the past 5 years: PCRX reported negative net income in multiple years.
  • PCRX had a positive operating cash flow in 4 of the past 5 years.
PCRX Yearly Net Income VS EBIT VS OCF VS FCFPCRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

1.2 Ratios

  • PCRX's Return On Assets of 1.65% is amongst the best of the industry. PCRX outperforms 81.25% of its industry peers.
  • PCRX's Return On Equity of 2.95% is amongst the best of the industry. PCRX outperforms 82.29% of its industry peers.
  • PCRX has a Return On Invested Capital of 3.63%. This is amongst the best in the industry. PCRX outperforms 82.29% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for PCRX is significantly below the industry average of 12.96%.
Industry RankSector Rank
ROA 1.65%
ROE 2.95%
ROIC 3.63%
ROA(3y)-0.93%
ROA(5y)2.13%
ROE(3y)-1.97%
ROE(5y)4.66%
ROIC(3y)4.3%
ROIC(5y)4.55%
PCRX Yearly ROA, ROE, ROICPCRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20

1.3 Margins

  • PCRX has a better Profit Margin (2.99%) than 80.73% of its industry peers.
  • With an excellent Operating Margin value of 8.88%, PCRX belongs to the best of the industry, outperforming 81.25% of the companies in the same industry.
  • PCRX's Operating Margin has improved in the last couple of years.
  • The Gross Margin of PCRX (79.17%) is better than 84.90% of its industry peers.
  • In the last couple of years the Gross Margin of PCRX has remained more or less at the same level.
Industry RankSector Rank
OM 8.88%
PM (TTM) 2.99%
GM 79.17%
OM growth 3Y-15.96%
OM growth 5Y11.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.7%
GM growth 5Y0.27%
PCRX Yearly Profit, Operating, Gross MarginsPCRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so PCRX is destroying value.
  • PCRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
PCRX Yearly Shares OutstandingPCRX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
PCRX Yearly Total Debt VS Total AssetsPCRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

  • An Altman-Z score of 1.90 indicates that PCRX is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • With a decent Altman-Z score value of 1.90, PCRX is doing good in the industry, outperforming 62.50% of the companies in the same industry.
  • The Debt to FCF ratio of PCRX is 3.03, which is a good value as it means it would take PCRX, 3.03 years of fcf income to pay off all of its debts.
  • The Debt to FCF ratio of PCRX (3.03) is better than 91.67% of its industry peers.
  • PCRX has a Debt/Equity ratio of 0.52. This is a neutral value indicating PCRX is somewhat dependend on debt financing.
  • PCRX has a worse Debt to Equity ratio (0.52) than 61.98% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.52
Debt/FCF 3.03
Altman-Z 1.9
ROIC/WACC0.47
WACC7.74%
PCRX Yearly LT Debt VS Equity VS FCFPCRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M 800M

2.3 Liquidity

  • A Current Ratio of 5.26 indicates that PCRX has no problem at all paying its short term obligations.
  • With a decent Current ratio value of 5.26, PCRX is doing good in the industry, outperforming 65.10% of the companies in the same industry.
  • A Quick Ratio of 3.78 indicates that PCRX has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 3.78, PCRX is in line with its industry, outperforming 59.38% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.26
Quick Ratio 3.78
PCRX Yearly Current Assets VS Current LiabilitesPCRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • PCRX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -18.07%.
  • The Earnings Per Share has been growing slightly by 3.64% on average over the past years.
EPS 1Y (TTM)-18.07%
EPS 3Y0.51%
EPS 5Y3.64%
EPS Q2Q%-37.36%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%5.14%

3.2 Future

  • Based on estimates for the next years, PCRX will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.23% on average per year.
  • Based on estimates for the next years, PCRX will show a small growth in Revenue. The Revenue will grow by 6.16% on average per year.
EPS Next Y32.15%
EPS Next 2Y22.15%
EPS Next 3Y16.67%
EPS Next 5Y11.23%
Revenue Next Year8.26%
Revenue Next 2Y8.81%
Revenue Next 3Y7.54%
Revenue Next 5Y6.16%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
PCRX Yearly Revenue VS EstimatesPCRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M 800M 1B
PCRX Yearly EPS VS EstimatesPCRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 2 3 4

More info and screens

Find the best growth stocksShow best growing peers

9

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 8.33, the valuation of PCRX can be described as reasonable.
  • Compared to the rest of the industry, the Price/Earnings ratio of PCRX indicates a rather cheap valuation: PCRX is cheaper than 93.23% of the companies listed in the same industry.
  • PCRX's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.10.
  • With a Price/Forward Earnings ratio of 6.30, the valuation of PCRX can be described as very cheap.
  • Based on the Price/Forward Earnings ratio, PCRX is valued cheaper than 93.75% of the companies in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 28.06, PCRX is valued rather cheaply.
Industry RankSector Rank
PE 8.33
Fwd PE 6.3
PCRX Price Earnings VS Forward Price EarningsPCRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • PCRX's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. PCRX is cheaper than 95.31% of the companies in the same industry.
  • 94.79% of the companies in the same industry are more expensive than PCRX, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 7.25
EV/EBITDA 6.21
PCRX Per share dataPCRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

  • PCRX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The decent profitability rating of PCRX may justify a higher PE ratio.
  • A more expensive valuation may be justified as PCRX's earnings are expected to grow with 16.67% in the coming years.
PEG (NY)0.26
PEG (5Y)2.29
EPS Next 2Y22.15%
EPS Next 3Y16.67%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • PCRX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PACIRA BIOSCIENCES INC

NASDAQ:PCRX (2/27/2026, 8:26:16 PM)

After market: 21.91 0 (0%)

21.91

-0.68 (-3.01%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-26
Earnings (Next)05-06
Inst Owners114.44%
Inst Owner Change-2.99%
Ins Owners0.79%
Ins Owner Change16.54%
Market Cap900.50M
Revenue(TTM)N/A
Net Income(TTM)21.44M
Analysts76.92
Price Target30.31 (38.34%)
Short Float %19.55%
Short Ratio8.74
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)3.71%
Min EPS beat(2)2.13%
Max EPS beat(2)5.28%
EPS beat(4)4
Avg EPS beat(4)4.05%
Min EPS beat(4)1.99%
Max EPS beat(4)6.81%
EPS beat(8)6
Avg EPS beat(8)5.89%
EPS beat(12)7
Avg EPS beat(12)1.4%
EPS beat(16)8
Avg EPS beat(16)-3.85%
Revenue beat(2)0
Avg Revenue beat(2)-3.29%
Min Revenue beat(2)-3.59%
Max Revenue beat(2)-2.99%
Revenue beat(4)0
Avg Revenue beat(4)-3.23%
Min Revenue beat(4)-5.92%
Max Revenue beat(4)-0.42%
Revenue beat(8)1
Avg Revenue beat(8)-2.14%
Revenue beat(12)1
Avg Revenue beat(12)-2.68%
Revenue beat(16)1
Avg Revenue beat(16)-2.53%
PT rev (1m)0%
PT rev (3m)-19.69%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-2.75%
EPS NY rev (1m)0%
EPS NY rev (3m)2.87%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.11%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.99%
Valuation
Industry RankSector Rank
PE 8.33
Fwd PE 6.3
P/S 1.26
P/FCF 7.25
P/OCF 6.37
P/B 1.24
P/tB 2.78
EV/EBITDA 6.21
EPS(TTM)2.63
EY12%
EPS(NY)3.48
Fwd EY15.86%
FCF(TTM)3.02
FCFY13.79%
OCF(TTM)3.44
OCFY15.71%
SpS17.44
BVpS17.69
TBVpS7.9
PEG (NY)0.26
PEG (5Y)2.29
Graham Number32.36
Profitability
Industry RankSector Rank
ROA 1.65%
ROE 2.95%
ROCE 5.34%
ROIC 3.63%
ROICexc 4.58%
ROICexgc 7.99%
OM 8.88%
PM (TTM) 2.99%
GM 79.17%
FCFM 17.33%
ROA(3y)-0.93%
ROA(5y)2.13%
ROE(3y)-1.97%
ROE(5y)4.66%
ROIC(3y)4.3%
ROIC(5y)4.55%
ROICexc(3y)6.05%
ROICexc(5y)7.29%
ROICexgc(3y)13.64%
ROICexgc(5y)24.93%
ROCE(3y)6.32%
ROCE(5y)6.69%
ROICexgc growth 3Y-33.29%
ROICexgc growth 5Y14.33%
ROICexc growth 3Y-3.13%
ROICexc growth 5Y10.2%
OM growth 3Y-15.96%
OM growth 5Y11.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.7%
GM growth 5Y0.27%
F-Score7
Asset Turnover0.55
Health
Industry RankSector Rank
Debt/Equity 0.52
Debt/FCF 3.03
Debt/EBITDA 2.44
Cap/Depr 18.95%
Cap/Sales 2.4%
Interest Coverage 4.07
Cash Conversion 91.52%
Profit Quality 579.36%
Current Ratio 5.26
Quick Ratio 3.78
Altman-Z 1.9
F-Score7
WACC7.74%
ROIC/WACC0.47
Cap/Depr(3y)22.15%
Cap/Depr(5y)83.49%
Cap/Sales(3y)2.76%
Cap/Sales(5y)5.11%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-18.07%
EPS 3Y0.51%
EPS 5Y3.64%
EPS Q2Q%-37.36%
EPS Next Y32.15%
EPS Next 2Y22.15%
EPS Next 3Y16.67%
EPS Next 5Y11.23%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%5.14%
Revenue Next Year8.26%
Revenue Next 2Y8.81%
Revenue Next 3Y7.54%
Revenue Next 5Y6.16%
EBIT growth 1Y-45.68%
EBIT growth 3Y-8.41%
EBIT growth 5Y23.37%
EBIT Next Year1.3%
EBIT Next 3Y6.32%
EBIT Next 5Y6.85%
FCF growth 1Y-4.68%
FCF growth 3Y30.84%
FCF growth 5Y24.28%
OCF growth 1Y-5.2%
OCF growth 3Y14.64%
OCF growth 5Y21.85%

PACIRA BIOSCIENCES INC / PCRX FAQ

What is the ChartMill fundamental rating of PACIRA BIOSCIENCES INC (PCRX) stock?

ChartMill assigns a fundamental rating of 6 / 10 to PCRX.


What is the valuation status for PCRX stock?

ChartMill assigns a valuation rating of 9 / 10 to PACIRA BIOSCIENCES INC (PCRX). This can be considered as Undervalued.


How profitable is PACIRA BIOSCIENCES INC (PCRX) stock?

PACIRA BIOSCIENCES INC (PCRX) has a profitability rating of 7 / 10.


What is the valuation of PACIRA BIOSCIENCES INC based on its PE and PB ratios?

The Price/Earnings (PE) ratio for PACIRA BIOSCIENCES INC (PCRX) is 8.33 and the Price/Book (PB) ratio is 1.24.